Escitalopram

Drug Profile

Escitalopram

Alternative Names: Cipralex; Entact; Lexapro; LU-26054; MLD-55; S-citalopram; Seroplex; Sipralex; Sipralexa

Latest Information Update: 04 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Developer Allergan; Forest Laboratories; Lundbeck A/S; Mochida Pharmaceutical
  • Class Antidepressants; Anxiolytics; Benzofurans; Fluorobenzenes; Nitriles; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Apr 2018 The Drug Committee of Ministry of Health, Labour and Welfare in Japan grants a 2-year extension of market exclusivity to escitalopram for Depression
  • 20 Nov 2015 Registered for Social phobia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top